Some of the most recent drug developments for T2DM and obesity are the triagonists for GLP-1R, GIPR, and GCGR (GLP-1R/GIPR/GCGR). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.